Trial Profile
A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy and Immunocompromised Adults
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Abdavomeran (Primary) ; BNT 162a1 (Primary) ; Pidacmeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors BioNTech
- 12 Sep 2023 Planned number of patients changed from 618 to 638.
- 01 Jun 2022 Status changed from active, no longer recruiting to completed.
- 12 Jan 2022 Status changed from recruiting to active, no longer recruiting.